Molecular radiotheranostics for neuroendocrine tumours.

View/ Open
Publication Date
2017-10Author
Navalkissoor, S
Flux, G
Bomanji, J
Type
Journal Article
Metadata
Show full item recordAbstract
This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.
Collections
Version of record
Subject
Humans
Neuroendocrine Tumors
Radionuclide Imaging
Research team
Radioisotope Physics
Language
eng
License start date
2017-10
Citation
Clinical medicine (London, England), 2017, 17 (5), pp. 462 - 468